Evidence map›Paper›PMID 41236513›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Novel compounds with promising HuH-7 inhibitory activity as new cancer drug candidates: derivatives of N,N'-diphenylurea linked with 1,2,3-triazole.

Yajie Guo, Huibao Long, Haoying Zhang, Dan Wang, Haidong Wu, Xuxiang Chen, Longfei Mao, En Gao, Tong Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yajie GuoDepartment of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Huibao LongDepartment of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Haoying ZhangSchool of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.
Dan WangSchool of Public Health, Southern Medical University, Guangzhou, Guangdong, China.
Haidong WuDepartment of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Xuxiang ChenDepartment of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Longfei MaoCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
En GaoSchool of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.
Tong WangDepartment of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted cancer drug therapy has emerged as a critical treatment modality for advanced hepatocellular carcinoma (HCC). The discovery and development of novel anti-HCC drug therapeutics with improved pharmacological properties remains an urgent priority in oncology drug discovery. In this study, we designed and synthesised a new series of 1,2,3-triazole-cored structures incorporating aryl urea. Fifteen analogs were prepared

Indexed as

Antineoplastic AgentsPhenylurea CompoundsTriazolesApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsPhenylurea CompoundsTriazoles1,2,3-triazoledithiocarbamatehepatocellular carcinoma (HCC)targeted anti-cancer drugurea

Identifiers

PMID41236513
PMCPMC12621342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.